Balyasny Asset Management
CYTK icon

Balyasny Asset Management’s Cytokinetics CYTK Stock Holding History

Balyasny Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.96M Sell
105,600
-252,900
-71% -$16.1M 0.01% 1208
2025
Q4 		$22.8M Sell
358,500
-2,100
-0.6% -$131K 0.03% 645
2025
Q3 		$19.8M Buy
+360,600
New +$14.9M 0.03% 722
2024
Q4 		– Sell
-4,700
Closed -$248K – 2842
2024
Q3 		$248K Sell
4,700
-196,400
-98% -$10.9M ﹤0.01% 2503
2024
Q2 		$10.9M Sell
201,100
-50,000
-20% -$3.02M 0.02% 844
2024
Q1 		$17.6M Sell
251,100
-89,000
-26% -$6.88M 0.03% 672
2023
Q4 		$28.4M Buy
340,100
+294,800
+651% +$10.7M 0.05% 474
2023
Q3 		$1.33M Buy
+45,300
New +$1.51M ﹤0.01% 1494
2020
Q4 		– Sell
-40,000
Closed -$866K – 1395
2020
Q3 		$866K Buy
+40,000
New +$936K 0.01% 1026

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Balyasny Asset Management's CYTK Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Cytokinetics (CYTK) in Q1 2026: 992,545 shares worth $65.4M. The stake represents 0.08% of the portfolio and ranks #268 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CYTK as recently as Q3 2024.

Balyasny Asset Management first reported a position in CYTK in Q4 2015 and has held it in 21 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Balyasny Asset Management held 992,545 shares of Cytokinetics worth $65.4M as of Q1 2026.
  • Cytokinetics was a new Balyasny Asset Management position in Q1 2026.
  • Cytokinetics made up 0.08% of Balyasny Asset Management's portfolio in Q1 2026, its #268 holding.
  • Balyasny Asset Management first reported a position in Cytokinetics in Q4 2015 and has held it in 21 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.